Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

DOI Full Paper Access

328

Citations

21

References

2018

Year

Emma Guttman‐Yassky, Patrick M. Brunner, Avidan U. Neumann, Saakshi Khattri, Ana B. Pavel, Kunal Malik, Giselle Singer, Danielle Baum, Patricia Gilleaudeau, Mary Sullivan‐Whalen,

Journal of the American Academy of Dermatology

Abstract

Fezakinumab was well-tolerated, with sustained clinical improvements after last drug dosing.

References

	Year	Citations

Page 1